Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Pediatrics
Published in: Indian Journal of Pediatrics 2/2024

30-09-2023 | Hemolytic Uremic Syndrome | Scientific Letter

Optimizing the Long-Term Therapy with Eculizumab (ECU) for Atypical Hemolytic Uremic Syndrome (aHUS)

Authors: Luisa Santangelo, Giuseppe Stefano Netti, Sebastiano Mazza, Francesca Zito, Valeria Catalano, Marida Martino, Diletta Domenica Torres, Vincenza Carbone, Elena Ranieri, Mario Giordano

Published in: Indian Journal of Pediatrics | Issue 2/2024

Login to get access

Excerpt

To the Editor: Eculizumab has dramatically improved both the patient and kidney survival of subjects with atypical Hemolytic Uremic Syndrome (aHUS) [1, 2]. However, its optimal long-term treatment schedule and duration is still a matter of debate [3]. Here we analyze the long-term clinical course of 6 pediatric patients treated with modified Eculizumab schedule. …
Appendix
Available only for authorised users
Literature
1.
Fakhouri F, Fila M, Provôt F, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol. 2017;12:50–9.CrossRefPubMed
2.
Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15–39.CrossRefPubMed
3.
Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)- a question to be addressed in a scientific way. Pediatr Nephrol. 2019;34:943–9.CrossRefPubMed
4.
Gurevich E, Landau D. Pharmacological management of atypical hemolytic uremic syndrome in pediatric patients: current and future. Paediatr Drugs. 2023;25:193–202.CrossRefPubMedPubMedCentral
Metadata
Title
Optimizing the Long-Term Therapy with Eculizumab (ECU) for Atypical Hemolytic Uremic Syndrome (aHUS)
Authors
Luisa Santangelo
Giuseppe Stefano Netti
Sebastiano Mazza
Francesca Zito
Valeria Catalano
Marida Martino
Diletta Domenica Torres
Vincenza Carbone
Elena Ranieri
Mario Giordano
Publication date
30-09-2023
Publisher
Springer India
Published in
Indian Journal of Pediatrics / Issue 2/2024
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-023-04817-0

Other articles of this Issue 2/2024

Indian Journal of Pediatrics 2/2024 Go to the issue

Scientific Letter

Acute Necrotizing Encephalopathy of Childhood Associated with Human Metapneumovirus

Correspondence

Pointers of  Genetic Susceptibility in an Infant with Pulmonary Tuberculosis

Review Article

Relapsed/Refractory T- Acute Lymphoblastic Leukemia — Current Options and Future Directions

Scientific Letter

Severe Hemolytic Anemia due to Erythrocyte Adenylate Kinase Deficiency due to a Novel Missense Mutation (c.518T>G)

Original Article

Translation and Psychometric Evaluation of the Hindi Language Version of the Pediatric Nausea Assessment Tool (PeNAT) in the Indian Population

Clinical Brief

Tolvaptan for Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in a Child with Corpus Callosum Agenesis